Engage with the Experts at Worldwide to Study Your Lupus Nephritis Therapy

The Lupus Foundation of America estimates the worldwide prevalence of lupus at approximately 5 million people.[1] Of those, nearly 60% will develop lupus nephritis (LN), an inflammation of the kidneys that compromises kidney function and can lead to end-stage renal disease (ESRD).

One difficulty for many people who have LN is that they don’t know they have it, particularly when the condition is in its early stages. Until LN is detected in a clinical test, an individual may simply notice darker-than-normal urine or foamy, frothy urine.

This poses difficulties for LN researchers, too. How do you source and screen a suitable population of study participants, particularly if you seek people whose LN is in the early stages, when so many people do not know they have the condition?

With more than 30 years of experience supporting researchers targeting immune-mediated inflammatory disorders (IMID), Worldwide is an internationally acclaimed expert in clinical trial management. We offer full-service Phase I-Phase IV trial support, as well as real-world evidence clinical research services that can help you track the long-term effects of your LN therapy. We have relationships with clinicians and facilities in more than 60 countries, and our experts have deep scientific knowledge about inflammatory processes, clinical manifestations, and therapeutic targets. Combined with our deep operational knowledge about how to complete projects on time and on budget, Worldwide will change the way you’ve experienced CROs – in the best possible way.

[1] https://resources.lupus.org/entry/facts-and-statistics